Pfizer, Teva reach deal to allow generic Viagra

by The Associated Press

Pfizer says it reached a settlement with Teva Pharmaceuticals that allows the generic drugmaker to launch a copycat version of its popular erectile dysfunction drug Viagra in 2017.

Pfizer says Teva will pay an undisclosed royalty for a license to produce a of Viagra, one of New York-based Pfizer's best-selling drugs. Viagra generated about $1.14 billion in U.S. sales last year.

Pfizer's patent protecting Viagra from generic competition expires in April 2020, but Teva will be allowed to launch its generic version Dec. 11, 2017.

Pfizer Inc. had sued Teva in 2010 over the Israeli drugmaker's plans to introduce a generic version of Viagra.

The patent protecting another , Eli Lilly and Co.'s Cialis, also expires in 2017.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Canada high court voids Pfizer's Viagra patent

Nov 08, 2012

Canada's top court on Thursday stripped Pfizer of its patent for Viagra, saying the pharmaceutical giant failed in the patent to identify the active compound in the drug.

Slovenia to launch generic version of Viagra

Jul 31, 2009

Krka, the biggest drugmaker in Slovenia, said Friday that its generic version of the impotency drug Viagra would be launched in September and priced 30 percent cheaper than the original.

FDA approves first generic versions of Cymbalta

Dec 11, 2013

The Food and Drug Administration says it has approved the first generic versions of the blockbuster antidepressant drug Cymbalta, offering lower-cost access to one of the most widely prescribed treatments for depression, ...

S. Korea to approve Viagra generics

Mar 14, 2012

Three South Korean pharmaceutical firms will soon be allowed to produce generic versions of the anti-impotence drug Viagra despite a row over patents, officials said Wednesday.

Recommended for you

WHO: Millions of Ebola vaccine doses ready in 2015

11 hours ago

The World Health Organization says millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines will start being tested in March.

Added benefit of vedolizumab is not proven

Oct 23, 2014

Vedolizumab (trade name Entyvio) has been approved since May 2014 for patients with moderately to severely active Crohn disease or ulcerative colitis. In an early benefit assessment pursuant to the Act on the Reform of the ...

Seaweed menace may yield new medicines

Oct 22, 2014

An invasive seaweed clogging up British coasts could be a blessing in disguise. University of Greenwich scientists have won a cash award to turn it into valuable compounds which can lead to new, life-saving drugs.

User comments